Optic neuritis
Drug research and approvals for optic neuritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 54 studies of optic neuritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 54
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDNCT07762872 · Not reported · Junwei Hao, MD · starts Jul 20, 2026
- Cohort Study on Neuroimmune Diseases in the Reproductive AgeNCT07653984 · Not reported · Third Affiliated Hospital, Sun Yat-Sen University · starts Apr 21, 2024
- Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation ResearchNCT07623668 · Phase 3 · Oculis · starts May 28, 2026
- Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is SuspectedNCT07623252 · Not reported · First Affiliated Hospital of Guangxi Medical University · starts Jan 6, 2025
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With…NCT07557420 · Phase 3 · Alexion Pharmaceuticals, Inc. · starts Jul 20, 2026
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory…NCT07526493 · Phase 1 · Tongji Hospital · starts Apr 1, 2026
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderNCT07420296 · Phase 3 · Tianjin Medical University General Hospital · starts Jan 1, 2026
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyNCT07410039 · Phase 4 · Chinese PLA General Hospital · starts Feb 1, 2026
- Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis…NCT07377305 · Not applicable · Tang-Du Hospital · starts Dec 8, 2025
Approved 3
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 3 3
- Epoetin betaErythropoietin receptor agonist
- Glatiramer acetate
- SimvastatinHMG-CoA reductase inhibitor
Phase 2 10
- OpicinumabLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor
- PhenytoinSodium channel alpha subunit blocker
- AmilorideAmiloride-sensitive sodium channel, ENaC blocker
- ClemastineHistamine H1 receptor antagonist
- CholecalciferolVitamin D receptor agonist
- ErgocalciferolVitamin D receptor agonist
- Methylprednisolone acetateGlucocorticoid receptor agonist
- FingolimodSphingosine 1-phosphate receptor agonist
- AtaciceptTumor necrosis factor ligand superfamily member 13B inhibitor
- Efgartigimod alfaIgG receptor FcRn large subunit p51 antagonist
Phase 1 or earlier 3
- Lipoic acid, alpha
- CorticotropinMelanocortin receptor 2 agonist
- DalfampridineVoltage-gated potassium channel blocker
How its trials ended
74 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 17 whose ending is known, 18% met their primary endpoint, 12% missed it and 71% stopped early.
- Completed, result not reported2635%
- Status unknown1723%
- Ongoing1419%
- Stopped: enrollment or feasibility79%
- Met its primary endpoint34%
- Stopped: other or unclear34%
- Missed its primary endpoint23%
- Stopped: sponsor or business decision23%
| Jun 10, 2026 | A randomized, double-masked, placebo-controlled study assessing the efficacy and safety of privosegtor (OCS-05) in patients with optic neuritis (ON)Privosegtor (OCS-05) / Methylprednisolone | Oculis Operations Sàrl | Pending |
| May 24, 2017 | A phase II trial of high-dose vitamin D induction in optic neuritis (vitadon 2)Vitamin D | University of Calgary | Ongoing |
| Nov 18, 2015 | A multicenter, follow-up study to assess the long-term electrophysiologic and clinical outcomes in subjects previously enrolled in study 215on201BIIB033 (anti-lingo) | Biogen | Ongoing |
| Nov 9, 2021 | (R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy)…Treatment of Optic Neuritis | Trethera Corporation | Designated |
| Sep 21, 2021 | MelatoninTreatment of optic neuritis | WORPHMED Srl | Designated |
| Nov 17, 2014 | N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-iso…Treatment of optic neuritis | Oculis Operations Sàrl | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA